|
WO2009016043A2
(en)
*
|
2007-07-31 |
2009-02-05 |
Affibody Ab |
New albumin binding compositions, methods and uses
|
|
EP2437767B1
(en)
*
|
2009-06-01 |
2015-07-08 |
MedImmune, LLC |
Molecules with extended half-lives and uses thereof
|
|
CN107686513A
(zh)
*
|
2010-03-08 |
2018-02-13 |
通用电气医疗集团生物工艺研发股份公司 |
免疫球蛋白G Fc区结合多肽
|
|
WO2011136361A1
(ja)
*
|
2010-04-30 |
2011-11-03 |
株式会社 三和化学研究所 |
生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
|
|
EP2590993B1
(en)
*
|
2010-07-09 |
2015-05-06 |
Affibody AB |
Polypeptides
|
|
ES2667100T3
(es)
*
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
|
CN106986940A
(zh)
|
2010-09-28 |
2017-07-28 |
艾米琳制药有限责任公司 |
具有增强的作用持续时间的工程化多肽
|
|
EA032917B1
(ru)
*
|
2010-09-28 |
2019-08-30 |
Амилин Фармасьютикалс, Ллк |
Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
|
|
EP3514169B1
(en)
|
2010-11-26 |
2024-03-06 |
Molecular Partners AG |
Designed repeat proteins binding to serum albumin
|
|
JP6145088B2
(ja)
*
|
2011-05-21 |
2017-06-07 |
マクロジェニクス，インコーポレーテッド |
脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
|
|
EP2729481B1
(en)
*
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
CN103957926B
(zh)
*
|
2011-07-08 |
2018-07-03 |
安米林药品有限责任公司 |
具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
|
|
DK2817329T3
(en)
|
2012-02-20 |
2019-04-01 |
Swedish Orphan Biovitrum Ab Publ |
Polypeptides Binding to Human Complement Component C5.
|
|
EP2830665A1
(en)
*
|
2012-03-28 |
2015-02-04 |
Affibody AB |
Oral administration
|
|
JP2020033372A
(ja)
*
|
2012-03-28 |
2020-03-05 |
アフィボディ・アーベー |
経口投与
|
|
EP2844269A4
(en)
*
|
2012-03-28 |
2016-01-06 |
Amylin Pharmaceuticals Llc |
TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
|
|
BR112014029409B1
(pt)
|
2012-05-25 |
2022-11-29 |
Janssen Biotech, Inc |
Domínio de ligação a albumina isolado não natural, método para produção do mesmo, polinucleotídeo isolado, vetor isolado, célula hospedeira isolada, proteína de fusão e composição farmacêutica
|
|
KR102123457B1
(ko)
*
|
2012-09-25 |
2020-06-16 |
애피바디 에이비 |
알부민 결합 폴리펩타이드
|
|
US9745350B2
(en)
|
2012-10-05 |
2017-08-29 |
Affibody Ab |
HER3 binding polypeptides
|
|
WO2014064237A1
(en)
|
2012-10-25 |
2014-05-01 |
Affibody Ab |
Abd binding polypeptide
|
|
EP2912051B1
(en)
*
|
2012-10-25 |
2018-04-18 |
Affibody AB |
Method for the separation of proteins containing an albumin-binding domain
|
|
WO2014076179A1
(en)
|
2012-11-14 |
2014-05-22 |
Affibody Ab |
New polypeptide
|
|
USRE48805E1
(en)
|
2013-03-06 |
2021-11-02 |
Vision Global Holdings Ltd. |
Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
|
|
US9255262B2
(en)
|
2013-03-06 |
2016-02-09 |
Vision Global Holdings Ltd. |
Albumin-binding arginine deminase and the use thereof
|
|
HK1218534A1
(zh)
*
|
2013-03-14 |
2017-02-24 |
多伦多大学管理委员会 |
支架化肽文库以及其制备和筛选方法
|
|
SG11201505856TA
(en)
|
2013-03-14 |
2015-08-28 |
Daiichi Sankyo Co Ltd |
Novel binding proteins for pcsk9
|
|
EP2970406B1
(en)
|
2013-03-15 |
2017-12-13 |
Affibody AB |
New polypeptides
|
|
CA2908198A1
(en)
|
2013-04-18 |
2014-10-23 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
ES2688206T3
(es)
|
2013-06-17 |
2018-10-31 |
Armo Biosciences, Inc. |
Procedimiento de evaluación de la identidad y la estabilidad de proteínas
|
|
JP6767865B2
(ja)
|
2013-08-28 |
2020-10-14 |
スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） |
ヒト補体ｃ５に結合する安定なポリペプチド
|
|
MY176200A
(en)
|
2013-08-28 |
2020-07-24 |
Affibody Ab |
Binding polypeptides having a mutated scaffold
|
|
JP6509867B2
(ja)
|
2013-08-30 |
2019-05-08 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を治療するためにインターロイキン−１０を使用する方法
|
|
WO2015070060A1
(en)
|
2013-11-11 |
2015-05-14 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
EP3083675B1
(en)
|
2013-12-20 |
2018-03-07 |
Affibody AB |
Engineered albumin binding polypeptide
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
SG10201802098UA
(en)
|
2014-07-30 |
2018-04-27 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
|
LT3193930T
(lt)
|
2014-09-17 |
2019-10-25 |
Affibody Ab |
Nauji polipeptidai
|
|
MX2017004838A
(es)
|
2014-10-14 |
2017-10-16 |
Armo Biosciences Inc |
Composiciones de interleucina-15 y usos de estas.
|
|
ES2941234T3
(es)
|
2014-10-22 |
2023-05-19 |
Armo Biosciences Inc |
Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
|
|
MY186702A
(en)
|
2014-10-31 |
2021-08-11 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
|
MY188784A
(en)
|
2015-01-12 |
2021-12-31 |
Affibody Ab |
Il-17a-binding polypeptides
|
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
|
US11052133B2
(en)
|
2015-05-06 |
2021-07-06 |
Protomer Technologies, Inc. |
Glucose responsive insulins
|
|
US20160361415A1
(en)
|
2015-05-28 |
2016-12-15 |
Armo Biosciences, Inc. |
Methods of Using Interleukin-10 for Treating Diseases and Disorders
|
|
CA2994279A1
(en)
|
2015-08-04 |
2017-02-09 |
Duke University |
Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
|
|
EP4606387A3
(en)
|
2015-08-25 |
2025-11-19 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
CN107022031A
(zh)
*
|
2016-01-29 |
2017-08-08 |
中国人民解放军军事医学科学院微生物流行病研究所 |
融合蛋白HSA1-Vβ1及其应用
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
KR20190064600A
(ko)
|
2016-09-23 |
2019-06-10 |
듀크 유니버시티 |
Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
|
|
CN107952080A
(zh)
*
|
2016-10-14 |
2018-04-24 |
中国科学院过程工程研究所 |
一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
US11554097B2
(en)
|
2017-05-15 |
2023-01-17 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
US11680083B2
(en)
|
2017-06-30 |
2023-06-20 |
Duke University |
Order and disorder as a design principle for stimuli-responsive biopolymer networks
|
|
US11077199B2
(en)
*
|
2017-08-09 |
2021-08-03 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
|
US20200239575A1
(en)
*
|
2017-10-06 |
2020-07-30 |
University Of Utah Research Foundation |
A fusion protein for targeted therapy of autoimmune disease
|
|
WO2019071150A1
(en)
*
|
2017-10-06 |
2019-04-11 |
University Of Utah Research Foundation |
FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
|
|
WO2019147954A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
WO2019175176A1
(en)
|
2018-03-13 |
2019-09-19 |
Affibody Ab |
Polypeptides based on a novel scaffold
|
|
US12257308B2
(en)
|
2018-04-30 |
2025-03-25 |
Duke University |
Stimuli-responsive PEG-like polymer-based drug delivery platform
|
|
WO2020028806A1
(en)
|
2018-08-02 |
2020-02-06 |
Duke University |
Dual agonist fusion proteins
|
|
WO2020051541A1
(en)
*
|
2018-09-07 |
2020-03-12 |
Duke University |
Nanoparticulate drug delivery systems
|
|
EP3930687A4
(en)
|
2019-02-25 |
2023-06-07 |
The University of Chicago |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
|
|
US12441772B2
(en)
|
2019-06-04 |
2025-10-14 |
Molecular Partners Ag |
Designed ankyrin repeat domain with improved stability
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
EP3785726A1
(en)
|
2019-09-02 |
2021-03-03 |
Biotest AG |
Factor viii protein with increased half-life
|
|
JP2022546525A
(ja)
|
2019-09-02 |
2022-11-04 |
ビオテスト・アクチエンゲゼルシャフト |
延長された半減期を有する第ｖｉｉｉ因子タンパク質
|
|
WO2021089695A1
(en)
|
2019-11-05 |
2021-05-14 |
Affibody Ab |
Polypeptides
|
|
WO2021165226A1
(en)
|
2020-02-17 |
2021-08-26 |
Biotest Ag |
Subcutaneous administration of factor viii
|
|
EP3878515A1
(en)
*
|
2020-03-09 |
2021-09-15 |
Hober Biotech AB |
Therapeutic agent targeting her2
|
|
WO2022098745A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, delivery systems, and methods useful in tumor therapy
|
|
WO2022098743A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
|
|
JP2023554258A
(ja)
|
2020-12-21 |
2023-12-27 |
アフィボディ アクティエボラーグ |
新規のポリペプチド
|
|
US20240124533A1
(en)
|
2021-02-15 |
2024-04-18 |
Affibody Ab |
New her2-binding polypeptide
|
|
KR20240139058A
(ko)
|
2022-02-08 |
2024-09-20 |
애피바디 에이비 |
흉선 기질 림포포이에틴에 결합하는 단백질 z 변이체 및 이의 의학적 용도
|
|
US12139502B2
(en)
|
2022-05-18 |
2024-11-12 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|
|
WO2024034685A1
(ja)
|
2022-08-10 |
2024-02-15 |
興和株式会社 |
アフィボディミセル薬物複合体
|
|
AU2024221136A1
(en)
|
2023-02-17 |
2025-10-02 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|
|
WO2024227930A1
(en)
|
2023-05-04 |
2024-11-07 |
Affibody Ab |
New polypeptide
|
|
WO2025073871A1
(en)
|
2023-10-03 |
2025-04-10 |
Bicycletx Limited |
Bicyclic peptide ligand complexes specific for tfr1
|
|
WO2025158010A1
(en)
|
2024-01-25 |
2025-07-31 |
Affibody Ab |
Her2-binding polypeptide
|
|
CN121041473A
(zh)
*
|
2024-05-29 |
2025-12-02 |
烟台蓝纳成生物技术股份有限公司 |
一种双功能性融合蛋白、放射性核素标记物及其应用
|
|
CN118666961B
(zh)
*
|
2024-08-23 |
2024-11-26 |
通化安睿特生物制药股份有限公司 |
人白蛋白特异结合多肽及其应用
|